Optimal management of hypertensive patients with Type 2 diabetes and microalbuminuria

International Journal of Clinical Practice, Supplement

Volumn , Issue 98, 1998, Pages 13-20

  Mogensen, C E ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; HUMAN; HYPERTENSION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; ALBUMINURIA; CHRONIC KIDNEY FAILURE; DIABETIC ANGIOPATHY; REVIEW;

ANTIHYPERTENSIVE AGENT;

ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC;

EID: 0031593309     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (74)

1. Keen H, Chlouverakis C. An immunoassay method for urinary albumin at low concentrations. Lancet 1963; ii: 913-916.
2. Keen H, Chlouverakis C. Urinary albumin excretion and diabetes mellitus. Lancet 1964; ii: 1155.
3. Miles DW, Mogensen CE, Gundersen HJG. Radioimmunoassay for urinary albumin using a single antibody. Scand J Clin Lab Invest 1970; 26: 5-11.
4. Maschio G. The kidney in essential hypertension: a Cinderella of hypertension research. Nephrol Dial Transplant 1995; 10: 1986-1988.
5. Parving H-H, Jensen HÆ, Mogensen CE, Evrin PE. Increased urinary albumin excretion rate in benign essential hypertension. Lancet 1974; i: 1190-1192.
6. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in patients with essential hypertension. Cardiovascular and renal implications. In Mogensen CE (ed): The Kidney and Hypertension in Diabetes Mellitus, 4th ed. Boston, Dordrecth, London: Kluwer Academic Publishers, 1998: 569-584.
7. Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, Garcia-Robles R, Rodicio JL. Blood pressure and renal function: therapeutic implications. J Hypertension 1996; 14: 1259-1263.
8. Østerby R. Lessons from kidney biopsies. Diabetes Metab Rev 1996; 12: 151-174.
9. Feldt-Rasmussen B. The course of incipient and overt diabetic nephropathy: the perspective of more optimal insulin treatment. In: Mogensen CE (ed). The Kidney and Hypertension in Diabetes Mellitus, 4th edition. Boston, Dordrecht, London: Kluwer Academic Publishers, 1998: 435-442.
10. Mogensen CE, Poulsen PL, Heinsvig EM. Abnormal albuminuria in the monitoring of early renal changes in diabetes. In: Mogensen CE, Standl E (ed). Concepts for the Ideal Diabetes Clinic. Diabetes Forum Series, Volume IV. Berlin, New York: Walter de Gruyter, 1993: 289-313.
11. Poulsen PL. Office tests for microalbuminuria. In: Mogensen CE (ed). The Kidney and Hypertension in Diabetes Mellitus, 3rd edition. Boston, Dordrecht, London: Kluwer Academic Publishers, 1997: 127-134.
12. Poulsen PL, Mogensen CE. Clinical evaluation of a test for immediate and quantitative determination of urinary albumin/creatinine ratio. Diabetes Care 1998 ; 21(1): 97-98.
13. Vestbo E, Damsgaard EM, Frøland A, Mogensen CE. Urinary albumin excretion in a population based cohort. Diabetic Med 1995: 12: 488-493.
14. Redon J, Miralles A, Pascual JM, Baldó E, Robles RG, Carmena R. Hyperinsulinaemia as a determinant of microalbuminuria in essential hypertension. J Hypertens 1997; 15: 79-86.
15. Ferrannini E. The metabolic syndrome. In: Mogensen CE (ed). Target Organ Damage in the mature hypertensive. London: Science Press, 1993: 2.31-2.49.
16. Poulsen PL, Ebbehøj E, Hansen KW, Mogensen CE. High normo- or low microalbuminuria. Basis for intervention in IDDM. Kidney Int 1997; 63: S15-S18.
17. Poulsen PL, Ebbehøj E, Hansen KW, Mogensen CE. 24-h blood pressure and autonomic function is related to albumin excretion within the normoalbuminuric range in IDDM patients. Diabetologia 1997; 40: 718-725.
18. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 311: 89-93.
19. Mogensen CE. Definition of diabetic renal disease in insulin-dependent diabetes mellitus based on renal function tests. In: Mogensen CE (ed). The Kidney and Hypertension in Diabetes Mellitus, 3rd edition. Boston, Dordrecht, London: Kluwer Academic Publishers, 1997: 11-22.
20. Poulsen PL, Hansen KW, Mogensen CE. Ambulatory blood pressure in the transition from normo- to microalbuminuria. A longitudinal study in IDDM patients. Diabetes 1994; 43: 1248-1253.
21. Schleicher E, Kolm V, Ceol M, Nerlich A. Structural and functional changes in diabetic glomeropathy. Kidney Blood Press Res 1996; 19: 305-315.
22. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
23. The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587-593.
24. Mogensen CE, Keane WF, Bennett PH et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-1084.
25. The Euclid Study Group. A randomised placebo-controlled trial of lisinopril in normotensive insulin patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.
26. The EUCLID Study Group. The effect of lisinopril on retinopathy in people with insulin dependent diabetes mellitus (IDDM). Abstract. 16th SDF Congress, Helsinki, 1997.
27. Alaveras AEG, Thomas SM, Sagriotis A, Viberti GC. Promoters of progression of diabetic nephropathy. the relative roles of blood glucose and blood pressure control. Nephrol Dial Transplant 1997; 12(suppl.2): 71-74.
28. Nielsen S, Schmitz A. Clinical course of renal disease in Caucasian NIDDM-patients. In: Mogensen CE (ed). The Kidney and Hypertension in Diabetes Mellitus, 4th edition. Boston, Dordrecht, London: Kluwer Academic Publishers, 1998: 73-84.
29. Tanaka Y, Atsumi Y, Matsuoka K et al. Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM Patients. 1998.
30. Forsblom CM, Groop P-H, Ekstrand A et al. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care 1998; In press.
31. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
32. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996; 156: 286-289.
33. Cooper ME, McNally PG. Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria. In: Mogensen CE (ed). The Kidney and Hypertension in Diabetes Mellitus, 4th edition. Boston, Dordrecht, London: Kluwer Academic Publishers, 1998: 419-434.
34. Ravid M, Brosh D, Levi Z et al. Use of enalapril to attenuate decline in renal function in normotensive patients with type 2 diabetes mellitus. A randomized controlled trial. Ann Intern Med 1998; 128: 982-988.
35. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360.
36. Jarrett RJ, Viberti GC, Argyropoulos A et al. Microalbuminuria predicts mortality in non-insulin-dependent diabetes. Diabetic Med 1984; 1: 17-19.
37. Schmitz A, Væth M. Microalbuminuria: A major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabetic Med 1988; 5: 126-134.
38. Mattock MB, Morrish NJ, Viberti GC, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992; 41: 736-741.
39. Damsgaard EM, Frøland A, Jørgensen OD, Mogensen CE. Eight to nine year mortality in known non-insulin dependent diabetics and controls. Kidney Int 1992; 41: 731-735.
40. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993; 16: 996-1004.
41. Uusitupa M, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993; 36: 1175-1184.
42. Gall M-A, Borch-Johnsen K, Hougaard et al. Albuminuria and poor glycemic control predict mortality in non-insulin-dependent diabetes mellitus. Diabetes 1995; 44: 1303-1309.
43. MacLeod JM, Lutale J, Marshall SM. Albumin excretion and vascular deaths in NIDDM. Diabetologia 1995; 38: 610-616.
44. Stiegler H, Standl E, Schultz K et al. Morbidity, mortality, and albuminuria in type 2 diabetic patients: a three-year prospective study of a random cohort in general practice. Diabet Med 1992; 9: 646-653.
45. Beilin J, Stanto KG, McCann VJ et al. Microalbuminuria in type 2 diabetes: an independent predictor of cardiovascular mortality. Aust N Z J Med 1996; 26: 519-525.
46. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157: 1413-1418.
47. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as a predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988; ii: 530-533.
48. Damsgaard EM, Frøland A, Jørgensen OD, Mogensen CE. Microalbuminuria as a predictor of increased mortality in elderly people. BMJ 1990; 300: 297-300.
49. Knowler WC, Nelson RG, Pettitt DJ. Diabetes, hypertension, and kidney disease in the Pima Indians. In: Mogensen CE (ed). The Kidney and Hypertension in Diabetes Mellitus, 4th edition. Boston, Dordrecht, London: Kluwer Academic Publishers, 1998: 141-150.
50. Abraira C, Colwell J, Nuttall F et al and the Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VACSDM) Group. Cardiovascular events and correlates in the veterans affairs diabetes feasibility trial. Veterans affairs cooperative study on glycemic control and complications in Type II diabetes. Arch Intern Med 1997; 157: 181-188.
51. Yokoyama H, Tomonaga O, Hirayama M et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 1997; 40: 405-411.
52. Smulders YM, Rakic M, Stehouwer CDA et al. Determinants of progression of microalbuminuria in patients with NIDDM. Diabetes Care 1997; 20: 999-1005.
53. Mogensen CE. How to protect the kidney in diabetic patients. With special reference to IDDM. Diabetes 1997; 46(suppl. 2): S104-S111.
54. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-219.
55. Alberti KGMM, Zimmet PZ for the WHO Consultation. Definition, Diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabet Med 1998; 15: 539-553.
56. Pyorälä K, Olsson AG, Pedersen TR et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614-620.
57. UKPDS 33. An intensive blood glucose control policy with sulphonylureas or insulin reduces the risk of diabetic complications in patients with Type 2 diabetes. Lancet 1998; 352: 837-853.
58. UKPDS 34. Effect of an intensive blood glucose control policy with metformin on complications in Type 2 diabetic patients. Lancet 1998; 352: 854-865.
59. UKPDS 40. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes. BMJ 1998; 317: 720-726.
60. Turner R. Holman R. Stratton I et al for the United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: United Kingdom prospective diabetes study (UKPDS: 38). BMJ 1998; 317: 703-713.
61. Holman R, Turner R, Stratton I et al for the United Kingdom Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: United Kingdom prospective diabetes study (UKPDS: 39). BMJ 1998; 317: 713-720.
62. Turner RC, Millns H, Neil HA et al for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) BMJ 1998; 316: 823-828.
63. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982; 285: 685-688.
64. Tattersall Robin Bell. The quest for normoglycaemia: a historical perspective. Diabet Med 1994; 11: 618-635.
65. Alberti KGMM, Zimmet PZ, for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diab Med 1998; 15: 539-553.
66. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
67. Cooper ME, McNally PG. Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria In: Mogensen CE (ed): The Kidney and hypertension in Diabetes Mellitus Kluwer Academic Publications. 1998, 419-432.
68. Gaster B, Hirsch JB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998; 158: 134-140.
69. Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276(23): 1886-1892.
70. Hansson L, Zanchetti A, Carruthers SG et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
71. Tuomilehto J, Rastenyte D, Thisj L, Staessen J. Reduction of mortality and cardiovascular events in older diabetic patients with isolated systolic hypertension in Europe treated with nitrendipine-based antihypertensive therapy (Syst-Eur-Trial). Diabetes 1998; 47: A54 (abstract).
72. Hansson L, Lindhol LH, Lanke L et al. Principal results of the Captopril Prevention Project (CAPP). Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. Lancet, in press.
73. Hsuch WA, Law RE. Cardiovascular risk continuum: Implications of insulin resistance and diabetes. Am J Med 1998; 105(1A): 4S-14S.
74. Gæde P, Vedel P, Parving H-H, Pedersen O. The Steno type 2 study: Intensive multifactorial intervention delays progression in diabetic microand macroangiopathy in microalbuminuric type 2 diabetic patients. Diabetologia 1998; 41(1): abstract 7.